Compounds > sk&f 110679
Page last updated: 2024-11-12

sk&f 110679

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9919153
CHEMBL ID105462
SCHEMBL ID9726175
MeSH IDM0121904

Synonyms (38)

Synonym
bdbm50049479
(s)-6-amino-2-{(r)-2-[(s)-2-{(s)-2-[(r)-2-[(s)-2-amino-3-(3h-imidazol-4-yl)-propionylamino]-3-(1h-indol-3-yl)-propionylamino]-propionylamino}-3-(1h-indol-3-yl)-propionylamino]-3-phenyl-propionylamino}-hexanoic acid amide
(s)-6-amino-2-{(r)-2-[(s)-2-{(s)-2-[(r)-2-[(s)-2-amino-3-(1h-imidazol-4-yl)-propionylamino]-3-(1h-indol-3-yl)-propionylamino]-propionylamino}-3-(1h-indol-3-yl)-propionylamino]-3-phenyl-propionylamino}-hexanoic acid amide
NCGC00167341-01
CHEMBL105462 ,
FT-0650597
sk&f 110679
gh-releasing peptide
(d-trp(2)-d-phe(5))ghrp
his(1)-lys(6)-ghrp
ghrp, his(1)-lys(6)-
l-lysinamide, l-histidyl-d-tryptophyl-l-alanyl-l-tryptophyl-d-phenylalanyl-
skf 110679
histidyl-tryptophyl-alanyl-tryptophyl-phenylalanyl-lysinamide
his-trp-ala-trp-phe-lysnh2
sk&f-110679
unii-4h7n4i6x6a
gh-releasing hexapeptide 6
4h7n4i6x6a ,
skf-110679
his-d-trp-ala-trp-d-phe-lys nh2
hexapeptide 2
u-75799e
SCHEMBL9726175
mfcd00872694
AKOS028109152
l-histidyl-d-tryptophyl-l-alanyl-l-tryptophyl-d-phenylalanyl-l-lysinamide
(d-trp7,ala8,d-phe10)-a-msh (6-11) amide
bdbm263227
us9708370, ghrp-6
DTXSID30904007
Q5611751
his-d-trp-ala-trp-d-phe-lysnh2
his-dtrp-ala-trp-dphe-lys-nh2
his-dtrp-ala-trp-dphe-lysnh2
h-his-d-trp-ala-trp-d-phe-lys-nh2
(2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide
AKOS040758818

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In vivo potency in swine after iv dosing is reported, and ED50 was found to be 30 nmol/kg of body weight for the most potent compound."( Novel orally active growth hormone secretagogues.
Andersen, PH; Ankersen, M; Hansen, BS; Hansen, TK; Johansen, NL; Lau, J; Lundt, BF; Madsen, K; Nielsen, KK; Peschke, B; Raun, K; Thøgersen, H, 1998)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Platelet glycoprotein 4Rattus norvegicus (Norway rat)IC50 (µMol)1.82001.82001.95002.0800AID698140
Growth hormone secretagogue receptor type 1Homo sapiens (human)IC50 (µMol)2.00320.00040.58926.0000AID1634379; AID698139; AID73176
Growth hormone secretagogue receptor type 1Homo sapiens (human)Ki0.00600.00020.03360.0906AID75338
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Growth hormone secretagogue receptor type 1Rattus norvegicus (Norway rat)EC50 (µMol)0.00580.00130.01540.0600AID175853; AID195900
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (47)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayGrowth hormone secretagogue receptor type 1Homo sapiens (human)
spermatogenesisGrowth hormone secretagogue receptor type 1Homo sapiens (human)
learning or memoryGrowth hormone secretagogue receptor type 1Homo sapiens (human)
actin polymerization or depolymerizationGrowth hormone secretagogue receptor type 1Homo sapiens (human)
adult feeding behaviorGrowth hormone secretagogue receptor type 1Homo sapiens (human)
response to hormoneGrowth hormone secretagogue receptor type 1Homo sapiens (human)
hormone-mediated signaling pathwayGrowth hormone secretagogue receptor type 1Homo sapiens (human)
negative regulation of norepinephrine secretionGrowth hormone secretagogue receptor type 1Homo sapiens (human)
growth hormone secretionGrowth hormone secretagogue receptor type 1Homo sapiens (human)
response to foodGrowth hormone secretagogue receptor type 1Homo sapiens (human)
negative regulation of appetiteGrowth hormone secretagogue receptor type 1Homo sapiens (human)
positive regulation of appetiteGrowth hormone secretagogue receptor type 1Homo sapiens (human)
response to follicle-stimulating hormoneGrowth hormone secretagogue receptor type 1Homo sapiens (human)
response to estradiolGrowth hormone secretagogue receptor type 1Homo sapiens (human)
negative regulation of interleukin-1 beta productionGrowth hormone secretagogue receptor type 1Homo sapiens (human)
negative regulation of interleukin-6 productionGrowth hormone secretagogue receptor type 1Homo sapiens (human)
negative regulation of tumor necrosis factor productionGrowth hormone secretagogue receptor type 1Homo sapiens (human)
cellular response to insulin stimulusGrowth hormone secretagogue receptor type 1Homo sapiens (human)
ghrelin secretionGrowth hormone secretagogue receptor type 1Homo sapiens (human)
positive regulation of multicellular organism growthGrowth hormone secretagogue receptor type 1Homo sapiens (human)
regulation of hindgut contractionGrowth hormone secretagogue receptor type 1Homo sapiens (human)
positive regulation of insulin-like growth factor receptor signaling pathwayGrowth hormone secretagogue receptor type 1Homo sapiens (human)
positive regulation of fatty acid metabolic processGrowth hormone secretagogue receptor type 1Homo sapiens (human)
negative regulation of insulin secretionGrowth hormone secretagogue receptor type 1Homo sapiens (human)
decidualizationGrowth hormone secretagogue receptor type 1Homo sapiens (human)
insulin-like growth factor receptor signaling pathwayGrowth hormone secretagogue receptor type 1Homo sapiens (human)
negative regulation of inflammatory responseGrowth hormone secretagogue receptor type 1Homo sapiens (human)
regulation of synapse assemblyGrowth hormone secretagogue receptor type 1Homo sapiens (human)
regulation of transmission of nerve impulseGrowth hormone secretagogue receptor type 1Homo sapiens (human)
regulation of growth hormone secretionGrowth hormone secretagogue receptor type 1Homo sapiens (human)
response to growth hormoneGrowth hormone secretagogue receptor type 1Homo sapiens (human)
cellular response to lipopolysaccharideGrowth hormone secretagogue receptor type 1Homo sapiens (human)
response to dexamethasoneGrowth hormone secretagogue receptor type 1Homo sapiens (human)
negative regulation of locomotion involved in locomotory behaviorGrowth hormone secretagogue receptor type 1Homo sapiens (human)
cellular response to thyroid hormone stimulusGrowth hormone secretagogue receptor type 1Homo sapiens (human)
regulation of neurotransmitter receptor localization to postsynaptic specialization membraneGrowth hormone secretagogue receptor type 1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionGrowth hormone secretagogue receptor type 1Homo sapiens (human)
regulation of postsynapse organizationGrowth hormone secretagogue receptor type 1Homo sapiens (human)
positive regulation of small intestinal transitGrowth hormone secretagogue receptor type 1Homo sapiens (human)
response to L-glutamateGrowth hormone secretagogue receptor type 1Homo sapiens (human)
positive regulation of sprouting angiogenesisGrowth hormone secretagogue receptor type 1Homo sapiens (human)
positive regulation of eating behaviorGrowth hormone secretagogue receptor type 1Homo sapiens (human)
positive regulation of small intestine smooth muscle contractionGrowth hormone secretagogue receptor type 1Homo sapiens (human)
regulation of gastric motilityGrowth hormone secretagogue receptor type 1Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationGrowth hormone secretagogue receptor type 1Homo sapiens (human)
cellular response to insulin-like growth factor stimulusGrowth hormone secretagogue receptor type 1Homo sapiens (human)
negative regulation of macrophage apoptotic processGrowth hormone secretagogue receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
growth hormone secretagogue receptor activityGrowth hormone secretagogue receptor type 1Homo sapiens (human)
G protein-coupled receptor activityGrowth hormone secretagogue receptor type 1Homo sapiens (human)
growth hormone-releasing hormone receptor activityGrowth hormone secretagogue receptor type 1Homo sapiens (human)
peptide hormone bindingGrowth hormone secretagogue receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
plasma membraneGrowth hormone secretagogue receptor type 1Rattus norvegicus (Norway rat)
plasma membraneGrowth hormone secretagogue receptor type 1Homo sapiens (human)
cell surfaceGrowth hormone secretagogue receptor type 1Homo sapiens (human)
neuron projectionGrowth hormone secretagogue receptor type 1Homo sapiens (human)
membrane raftGrowth hormone secretagogue receptor type 1Homo sapiens (human)
synaptic membraneGrowth hormone secretagogue receptor type 1Homo sapiens (human)
Schaffer collateral - CA1 synapseGrowth hormone secretagogue receptor type 1Homo sapiens (human)
postsynapseGrowth hormone secretagogue receptor type 1Homo sapiens (human)
glutamatergic synapseGrowth hormone secretagogue receptor type 1Homo sapiens (human)
plasma membraneGrowth hormone secretagogue receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID195906Compound was tested against the effect of D-Lys3-GHRP-6 on the release of growth hormone from pituitary cells in rat1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Novel orally active growth hormone secretagogues.
AID698140Displacement of photoactivatable [125I]-Tyr-Bpa-Ala-Hexarelin from CD36 in Sprague-Dawley rat cardiac membranes incubated for 60 mins by densitometry2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Azapeptide analogues of the growth hormone releasing peptide 6 as cluster of differentiation 36 receptor ligands with reduced affinity for the growth hormone secretagogue receptor 1a.
AID195909Compound was tested against the effect of substance P antagonist on the release of growth hormone from pituitary cells in rat1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Novel orally active growth hormone secretagogues.
AID209315Compound was tested for efficacy against GH release upon iv administration in swine1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Novel orally active growth hormone secretagogues.
AID195921Tested in vitro for GH-releasing potency against rat pituitary cells.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
AID195900Tested for GH-releasing property using classical rat pituitary cell assay1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Novel orally active growth hormone secretagogues.
AID26649Half-life was evaluated in rats1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential.
AID21866Clearance rate is evaluated rats1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential.
AID175658Effective Concentration for GH secretion from rat pituitary cell was determined1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Development of a high specific activity sulfur-35-labeled sulfonamide radioligand that allowed the identification of a new growth hormone secretagogue receptor.
AID24485Compound was evaluated for half-life in humans1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential.
AID195929Tested in vitro for GH-releasing potency against rat pituitary cells.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
AID698139Displacement of [125I]ghrelin expressed in in LLC-PK1 cells incubated for 1 hr by gamma counting method2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
Azapeptide analogues of the growth hormone releasing peptide 6 as cluster of differentiation 36 receptor ligands with reduced affinity for the growth hormone secretagogue receptor 1a.
AID195907Compound was tested against the effect of L-692400 on the release of growth hormone from pituitary cells in rat1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Novel orally active growth hormone secretagogues.
AID195905Tested for GH-releasing property using classical rat pituitary cell assay1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Novel orally active growth hormone secretagogues.
AID180671The effective concentration against rat pituitary cell GH release assay2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
Modeling directed design and biological evaluation of quinazolinones as non-peptidic growth hormone secretagogues.
AID59637Compound was tested for minimum effective dose in dogs through iv dose1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential.
AID176149Tested in vivo for GH-releasing potency against anesthetized male rats1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
AID179869Tested in vivo for GH-releasing potency against anesthetized female rats1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
AID176046compound was evaluated for GH release in the rat pituitary cell culture assay1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential.
AID175853In vitro growth hormone release was determined in rat pituitary cell assay1998Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1
Potent 3-spiropiperidine growth hormone secretagogues.
AID18148Compound was evaluated for oral bioavailability in human1998Journal of medicinal chemistry, Aug-13, Volume: 41, Issue:17
Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential.
AID209313Compound was tested for GH-releasing potency against female Danish slaughter swine.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
AID209312Compound was tested for potency against GH release upon iv administration in swine1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Novel orally active growth hormone secretagogues.
AID75338Binding Affinity against Growth hormone secretagogue receptor of swine using [35S]MK-0677 as radioligand1996Journal of medicinal chemistry, Apr-26, Volume: 39, Issue:9
Development of a high specific activity sulfur-35-labeled sulfonamide radioligand that allowed the identification of a new growth hormone secretagogue receptor.
AID209310Compound was tested for GH-releasing potency against female Danish slaughter swine.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.
AID73176Binding affinity for human growth hormone GH secretagogue (hGHsr) receptor2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
Modeling directed design and biological evaluation of quinazolinones as non-peptidic growth hormone secretagogues.
AID195908Compound was tested against the effect of N-acetyl-Tyr-D-Arg(1-29)GHRH-NH2 on the release of growth hormone from pituitary cells in rat1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
Novel orally active growth hormone secretagogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (71.43)18.2507
2000's1 (14.29)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.24 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
l 692429
L 692429: stimulates release of growth hormone; RN refers to (R)-isomer; structure given in first source		3.7830
l 163191
[no description available]		4.0140
l 163255
L 163255: a growth hormone secretagogue; RN given for (R)-isomer; structure in first source		3.0910
cp 424391
CP 424391: a growth hormone secretagogue; structure in first source		210
hexarelin
hexarelin: a synthetic growth hormone releasing peptide; structurally similar to GHRP-6, with the substitution of D-Trp with its 2-methyl derivative; more potent & stable and less toxic than GHRP-6		3.5320
tabimorelin
tabimorelin: a growth hormone secretagogue; structure in first source		1.9910
ipamorelin
[no description available]		2.420
l 692585
[no description available]		3.0910peptide
l 162752
[no description available]		1.9910
ghrp-1
alanyl-histidyl-(2-naphthyl)alanyl-tryptophyl-phenylalanyl-lysinamide: amino acid sequence given in first source; a second generation growth hormone-releasing peptide		3.0910
ConditionIndicatedRelationship StrengthStudiesTrials